Core Viewpoint - Aimeike (300896) has successfully completed the registration of its first new cosmetic ingredient, "Glycyrrhizin Chalcone A," derived from a plant unique to China [1] Group 1 - The registered ingredient is a significant milestone for the company in the cosmetic industry [1] - The core component, Glycyrrhizin Chalcone A, highlights the potential of utilizing indigenous plant resources in cosmetic formulations [1]

Core Insights - The company has received approval for a new hair product, minoxidil, which is a key move in the hair health sector, offering both 2% and 5% formulations to meet diverse consumer needs [1] - The acquisition of 85% of Korean regenerative medical aesthetics company REGEN for $190 million marks a strategic milestone in the company's transition from a domestic hyaluronic acid leader to a global medical aesthetics solution provider [2] - The company expects improved performance in the second half of the year due to a low base, with a long-term outlook on increasing penetration in the medical aesthetics market [2] Product Development - The approval of minoxidil allows the company to leverage its medical aesthetics channel advantages, creating a "treatment + care" ecosystem for hair health [1] - The company has a robust pipeline with 12 Class III medical device product registrations, including botulinum toxin and lidocaine products, which are in the review stage [1] Acquisition Strategy - The acquisition of REGEN provides the company with a mature product matrix and immediate revenue contributions, while also enabling long-term growth through advancements in synthetic biology and global channel expansion [2] Financial Projections - The company is projected to achieve revenues of 2.72 billion, 3.18 billion, and 3.57 billion yuan, with net profits of 1.64 billion, 1.88 billion, and 2.10 billion yuan for the years 2025 to 2027 [2] Valuation Metrics - Corresponding P/E ratios are expected to be 33.4, 29.1, and 26.2 for the years 2025 to 2027, maintaining a "buy" rating [3]

Market Overview - The Shanghai Composite Index rose by 0.63% on October 20, with 26 out of 28 sectors experiencing gains, led by the communication and coal industries, which increased by 3.21% and 3.04% respectively [1] - The market saw a net outflow of 4.601 billion yuan in major funds, with 12 sectors recording net inflows, primarily in the communication sector, which attracted 4.397 billion yuan [1] Sector Performance - The communication sector had the highest net inflow of funds, contributing to its 3.21% increase, while the coal sector followed with a net inflow of 1.148 billion yuan [1] - Conversely, the non-ferrous metals sector experienced the largest net outflow, totaling 4.699 billion yuan, followed by the computer sector with a net outflow of 2.390 billion yuan [1] Beauty and Personal Care Industry - The beauty and personal care sector declined by 0.38%, with a net outflow of 24.996 million yuan [2] - Among the 29 stocks in this sector, 15 saw gains while 12 experienced declines [2] - The top net inflow stock was Shanghai Jahwa, with an inflow of 22.996 million yuan, followed by Liangmianzhen and Jiaheng Jiahua with inflows of 12.992 million yuan and 6.235 million yuan respectively [2] Individual Stock Performance - The stocks with the highest net outflows included Proya, Aimeike, and Huaxi Biology, with outflows of 26.186 million yuan, 23.826 million yuan, and 9.397 million yuan respectively [2] - A detailed table of stock performance indicates various changes in price and turnover rates, highlighting the dynamics within the beauty and personal care sector [3]

Group 1 - The medical beauty sector experienced a decline of 0.94% on October 20, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] - Major stocks in the medical beauty sector showed mixed performance, with *ST Meigu closing at 3.51, up 1.45%, and Jinbo Biological at 261.00, down 3.45% [1] Group 2 - The net outflow of main funds in the medical beauty sector was 41.23 million yuan, while retail investors saw a net inflow of 57.45 million yuan [1] - Specific stock fund flows indicated that *ST Meigu had a net inflow of 0.75%, while Huaxi Biological and Aimeike experienced net outflows of 8.64% and 6.24%, respectively [2]

Core Insights - Aimeike's stock price has declined by 6.40% year-to-date, with a 5.41% drop over the last five trading days and a 14.23% decline over the last 20 days [1] - The company reported a revenue of 1.299 billion yuan for the first half of 2025, a year-on-year decrease of 21.59%, and a net profit of 789 million yuan, down 29.57% year-on-year [2] Financial Performance - As of October 20, Aimeike's stock was trading at 166.15 yuan per share, with a market capitalization of 50.276 billion yuan [1] - The company has distributed a total of 3.887 billion yuan in dividends since its A-share listing, with 3.012 billion yuan distributed over the last three years [3] Shareholder Information - As of October 10, Aimeike had 56,100 shareholders, a decrease of 0.32% from the previous period, with an average of 3,716 circulating shares per shareholder, an increase of 0.32% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Huabao CSI Medical ETF, with notable changes in their holdings [3]

Investment Rating - The investment rating for the retail industry is "Positive" (maintained) [1] Core Insights - The report highlights the commencement of the Double 11 e-commerce promotion, emphasizing a trend of simplifying promotional strategies, extending sales cycles, and seeking new growth avenues. This shift allows consumer demand to take precedence and encourages brands to focus on long-term value building [23][24] - The report identifies a significant increase in the performance of domestic brands during the Double 11 event, with a notable presence in the beauty and skincare categories, indicating that domestic brands are no longer just supplementary to international brands [25][29] Summary by Sections Retail Market Review - The retail industry index closed at 2277.78 points, down 0.45%, outperforming the Shanghai Composite Index, which fell by 1.47% [5][12] - The supermarket sector showed the highest increase this week, with a growth rate of 1.75% [15][18] - Year-to-date, the jewelry sector has led with a growth of 30.14% [15][18] Retail Perspectives - The Double 11 e-commerce promotion has officially started, with key trends including simplification of promotional strategies, extended sales cycles, and strategic exploration for new growth [23][24] - Domestic brands are increasingly strengthening their market presence, with significant sales performance noted in live-streaming events [25][29] Investment Recommendations - Investment focus areas include: 1. **Gold and Jewelry**: Recommend brands with differentiated product offerings and consumer insights, such as Laopuhuang and Chaohongji [30][32] 2. **Offline Retail**: Highlighting companies that adapt to trends, such as Yonghui Supermarket and Aiyingshi [30][32] 3. **Cosmetics**: Emphasizing strong domestic brands during the Double 11 event, including Porcelain and Maogeping [30][32] 4. **Medical Aesthetics**: Focusing on companies with differentiated product lines, such as Aimeike and Kedi-B [30][32]

Investment Rating - The report maintains a positive outlook on the cosmetics and medical beauty sector, highlighting strong performance relative to the market [5][6]. Core Insights - The Tmall Double 11 event showcased strong sales for domestic brands, with significant demand for products from brands like Maogeping and Winona, indicating a robust market response [9][10]. - The cosmetics and medical beauty sector is expected to see continued growth, with Q3 performance meeting expectations and Q4 anticipated to benefit from promotional activities [10][11]. - The report emphasizes the importance of online channels, particularly Tmall and Douyin, in driving sales for domestic brands, which are gaining market share against international competitors [24][26]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector outperformed the market from October 10 to October 17, 2025, with the Shenwan Beauty Care Index declining by 2.5%, which is better than the overall market performance [5][6]. - Key stocks in the sector included Jiaheng Jiahu (+35.0%), Yiyi Co. (+18.6%), and Yanjing Co. (+15.6%), while Maogeping (-7.2%) and Shangmei Co. (-5.4%) lagged [6]. Sales and Market Trends - The report notes that the overall retail sales of cosmetics in China reached 291.5 billion yuan in the first eight months of 2025, with a year-on-year growth of 3.3% [10][16]. - The Tmall Double 11 event attracted over 10 million viewers, with domestic brands experiencing sell-out conditions, indicating strong consumer interest and demand [9][10]. Company Highlights - Han Shu, a brand under Shangmei Co., has shown significant improvement in Tmall channel performance, collaborating with popular influencers to enhance sales [9][10]. - The report highlights the strategic partnership of Han Shu with global ambassador Wang Jiaer, aiming to elevate the brand's international presence and market perception [20][21]. Investment Recommendations - The report recommends focusing on brands with strong online sales growth, such as Maogeping, Shangmei Co., and Shanghai Jahwa, while also monitoring companies like Proya and Marubi for potential performance improvements [12][13]. - In the medical beauty segment, the report suggests investing in companies with strong R&D capabilities and product pipelines, recommending Aimeike as a key player [12][13].

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry [2]. Core Views - The cosmetics and medical beauty sector has shown stronger performance than the market, with the Shenwan Beauty Care Index declining by 2.5% from October 10 to October 17, 2025, which is better than the overall market performance [4][5]. - The Tmall Double 11 event has seen significant success for domestic brands, with brands like Maogeping experiencing high demand and sold-out products [10]. - The overall performance for Q3 2025 is expected to meet expectations, with a continued upward trend into Q4, driven by promotional events [11][12]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector outperformed the market during the specified period, with the Shenwan Cosmetics Index down by 1.1%, which is 2.3 percentage points better than the Shenwan A Index [4][5]. - Key stocks in the sector included Jiaheng Jiahua (+35.0%), Yiyi Co. (+18.6%), and Yanjing Co. (+15.6%) [6]. Market Trends - The Tmall Double 11 event on October 15 attracted over 10 million viewers, with domestic brands like Maogeping experiencing supply shortages due to high demand [10]. - The overall sales performance is expected to improve in the coming weeks, particularly with the upcoming Douyin Double 11 event [10]. Q3 Performance Outlook - The demand for cosmetics remains robust, with retail sales growth in July and August outpacing the overall market [11]. - The total retail sales of cosmetics for the first eight months of 2025 reached 291.5 billion yuan, a year-on-year increase of 3.3% [11]. - Domestic brands are leveraging online channels effectively, with Han Shu achieving over 2 billion yuan in GMV in Q3 [12]. Company Highlights - Han Shu announced a global partnership with Wang Jiaer, enhancing its international presence and brand recognition [19][22]. - The report recommends focusing on companies with strong channel and brand matrices, such as Maogeping, Shanghai Jahwa, and Up Beauty [14]. E-commerce Data - The report highlights significant growth in e-commerce sales for various brands, with Han Shu achieving a 37% increase in GMV [15]. - The overall e-commerce landscape for domestic brands is expected to continue thriving, supported by promotional events and strategic partnerships [15][18]. Market Dynamics - The report notes that the Chinese skincare market is projected to reach 271.2 billion yuan in 2024, despite a slight decline in growth [26]. - Domestic brands are increasingly capturing market share, with a notable presence in the top ten rankings [26][27]. Investment Recommendations - The report suggests investing in companies with strong growth potential and robust product pipelines, particularly in the cosmetics and medical beauty sectors [14]. - Specific recommendations include Maogeping, Up Beauty, and Shanghai Jahwa for cosmetics, and Aimeike for medical beauty [14].

Core Viewpoint - The medical beauty sector experienced a decline of 2.52% on October 17, with Jinbo Biological leading the drop. The Shanghai Composite Index closed at 3839.76, down 1.95%, while the Shenzhen Component Index closed at 12688.94, down 3.04% [1]. Group 1: Market Performance - The medical beauty sector saw a net outflow of main funds amounting to 84.94 million yuan, while retail investors had a net inflow of 95.23 million yuan [1]. - Individual stocks in the medical beauty sector showed varied performance, with *ST Meigu closing at 3.46 yuan, up 0.29%, and Jinbo Biological closing at 270.32 yuan, down 3.86% [1]. Group 2: Fund Flow Analysis - Main funds for *ST Meigu recorded a net outflow of 8.72 million yuan, while retail investors had a net inflow of 4.88 million yuan [2]. - For Huaxi Biological, main funds experienced a net outflow of 9.24 million yuan, with retail investors seeing a net inflow of 9.06 million yuan [2]. - Aimeike faced a significant net outflow of 66.98 million yuan from main funds, while retail investors had a net inflow of 81.30 million yuan [2].

Group 1 - The medical sector experienced volatility, with the largest medical ETF in A-shares (512170) dropping over 2% in the afternoon, with real-time transactions exceeding 490 million yuan [1] - The ETF's latest scale is 25.73 billion yuan, ranking first among similar ETFs [1] - Notable declines were observed in constituent stocks, with Sanbo Brain Science falling over 6%, and other companies like Yingke Medical and Nanwei Medical dropping more than 4% [1] Group 2 - Ping An Securities indicated that the bidding environment for medical devices will remain favorable in 2025, with strong demand for ultrasound, CT, and MRI equipment driven by policy incentives [3] - The pharmaceutical and biotechnology sectors are currently affected by policy disruptions, but the long-term industry trend remains unchanged, with Chinese innovative drug companies gaining global competitiveness [3] - The medical ETF (512170) passively tracks the CSI Medical Index, with its top ten weighted stocks including WuXi AppTec, Mindray Medical, and others [3]